Your browser doesn't support javascript.
loading
Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cells.
Nkongolo, Shirin; Mahamed, Deeqa; Kuipery, Adrian; Sanchez Vasquez, Juan D; Kim, Samuel C; Mehrotra, Aman; Patel, Anjali; Hu, Christine; McGilvray, Ian; Feld, Jordan J; Fung, Scott; Chen, Diana; Wallin, Jeffrey J; Gaggar, Anuj; Janssen, Harry LA; Gehring, Adam J.
Affiliation
  • Nkongolo S; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Mahamed D; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Kuipery A; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Sanchez Vasquez JD; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Kim SC; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Mehrotra A; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Patel A; Gilead Sciences, Foster City, California, USA.
  • Hu C; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • McGilvray I; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Feld JJ; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Fung S; Multi-Organ Transplant Program, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Chen D; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Wallin JJ; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Gaggar A; Gilead Sciences, Foster City, California, USA.
  • Janssen H; Gilead Sciences, Foster City, California, USA.
  • Gehring AJ; Gilead Sciences, Foster City, California, USA.
J Clin Invest ; 133(1)2023 01 03.
Article in En | MEDLINE | ID: mdl-36594467
ABSTRACT
Accumulation of activated immune cells results in nonspecific hepatocyte killing in chronic hepatitis B (CHB), leading to fibrosis and cirrhosis. This study aims to understand the underlying mechanisms in humans and to define whether these are driven by widespread activation or a subpopulation of immune cells. We enrolled CHB patients with active liver damage to receive antiviral therapy and performed longitudinal liver sampling using fine-needle aspiration to investigate mechanisms of CHB pathogenesis in the human liver. Single-cell sequencing of total liver cells revealed a distinct liver-resident, polyclonal CD8+ T cell population that was enriched at baseline and displayed a highly activated immune signature during liver damage. Cytokine combinations, identified by in silico prediction of ligand-receptor interaction, induced the activated phenotype in healthy liver CD8+ T cells, resulting in nonspecific Fas ligand-mediated killing of target cells. These results define a CD8+ T cell population in the human liver that can drive pathogenesis and a key pathway involved in their function in CHB patients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatitis B, Chronic Type of study: Risk_factors_studies Limits: Humans Language: En Journal: J Clin Invest Year: 2023 Document type: Article Affiliation country: Canadá

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatitis B, Chronic Type of study: Risk_factors_studies Limits: Humans Language: En Journal: J Clin Invest Year: 2023 Document type: Article Affiliation country: Canadá